These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 10438382

  • 1. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy.
    Parkin NT, Lie YS, Hellmann N, Markowitz M, Bonhoeffer S, Ho DD, Petropoulos CJ.
    J Infect Dis; 1999 Sep; 180(3):865-70. PubMed ID: 10438382
    [Abstract] [Full Text] [Related]

  • 2. Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
    Ferrer E, Podzamczer D, Arnedo M, Fumero E, McKenna P, Rinehart A, Pérez JL, Barberá MJ, Pumarola T, Gatell JM, Gudiol F, Combine Study Team.
    J Infect Dis; 2003 Feb 15; 187(4):687-90. PubMed ID: 12599088
    [Abstract] [Full Text] [Related]

  • 3. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D, Schapiro JM, Lanier ER, Gradstein S, Gottesman G, Kedem E, Einhorn M, Grisaru-Soen G, Ofir M, Engelhard D, Grossman Z.
    Pediatr Infect Dis J; 2006 Nov 15; 25(11):1049-56. PubMed ID: 17072129
    [Abstract] [Full Text] [Related]

  • 4. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
    Caride E, Brindeiro R, Hertogs K, Larder B, Dehertogh P, Machado E, de Sá CA, Eyer-Silva WA, Sion FS, Passioni LF, Menezes JA, Calazans AR, Tanuri A.
    Virology; 2000 Sep 15; 275(1):107-15. PubMed ID: 11017792
    [Abstract] [Full Text] [Related]

  • 5. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
    Atkinson B, Isaacson J, Knowles M, Mazabel E, Patick AK.
    J Infect Dis; 2000 Aug 15; 182(2):420-7. PubMed ID: 10915071
    [Abstract] [Full Text] [Related]

  • 6. HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.
    Demeter LM, Ribaudo HJ, Erice A, Eshleman SH, Hammer SM, Hellmann NS, Fischl MA, AIDS Clinical Trials Group Protocol 388.
    Clin Infect Dis; 2004 Aug 15; 39(4):552-8. PubMed ID: 15356820
    [Abstract] [Full Text] [Related]

  • 7. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P.
    J Infect Dis; 2001 Jun 15; 183(12):1732-8. PubMed ID: 11372025
    [Abstract] [Full Text] [Related]

  • 8. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.
    Rusconi S, De Pasquale MP, Milazzo L, Moscatelli G, Bulgheroni E, Citterio P, d'Arminio-Monforte A, Moroni M, Galli M.
    Antivir Ther; 1997 Jan 15; 2(1):39-46. PubMed ID: 11322265
    [Abstract] [Full Text] [Related]

  • 9. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MM.
    J Infect Dis; 2000 Feb 15; 181(2):491-7. PubMed ID: 10669331
    [Abstract] [Full Text] [Related]

  • 10. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.
    Antivir Ther; 2006 Feb 15; 11(6):827-30. PubMed ID: 17310827
    [Abstract] [Full Text] [Related]

  • 11. Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.
    Rubio A, Gómez-Cano M, Puig T, Leal M, Pérez-Olmeda M, Ruiz L, Clotet B, Rey C, Zamora L, Xaus N, Soriano V.
    Antivir Ther; 1999 Feb 15; 4(1):45-9. PubMed ID: 10682128
    [Abstract] [Full Text] [Related]

  • 12. Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection.
    Call SA, Saag MS, Westfall AO, Raper JL, Pham SV, Tolson JM, Hellmann NS, Cloud GA, Johnson VA.
    J Infect Dis; 2001 Feb 01; 183(3):401-8. PubMed ID: 11133371
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy.
    Walter H, Schmidt B, Rascu A, Helm M, Moschik B, Paatz C, Kurowski M, Korn K, Uberla K, Harrer T.
    Antivir Ther; 2000 Dec 01; 5(4):249-56. PubMed ID: 11142619
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA, Leriche-Guerin K, Regis C, Bordes I, Cotte L, Detmer J, Kolberg J, Ritter J, Trépo C.
    J Med Virol; 2000 Jul 01; 61(3):352-9. PubMed ID: 10861645
    [Abstract] [Full Text] [Related]

  • 18. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.
    Hanna GJ, D'Aquila RT.
    Clin Infect Dis; 2001 Mar 01; 32(5):774-82. PubMed ID: 11229846
    [Abstract] [Full Text] [Related]

  • 19. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, Gu K, Hsu A, Brun S, Sun E.
    J Infect Dis; 2004 Jan 01; 189(1):51-60. PubMed ID: 14702153
    [Abstract] [Full Text] [Related]

  • 20. Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5).
    Hachiya A, Aizawa-Matsuoka S, Tanaka M, Takahashi Y, Ida S, Gatanaga H, Hirabayashi Y, Kojima A, Tatsumi M, Oka S.
    Antimicrob Agents Chemother; 2001 Feb 01; 45(2):495-501. PubMed ID: 11158746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.